secwatch.observer — SEC 8-K summary
======================================

Issuer:     LianBio (LIANY)
CIK:        0001831283
Form:       8-K
Filed at:   2023-11-13T23:59:59+00:00
Accession:  0001831283-23-000124
Event type: earnings
Sentiment:  neutral
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

LianBio Q3 net loss $24M, inks $350M BMS mavacamten deal, strategic review ongoing
--------------------------------------------------------------------------------

- Net loss of $24.0M in Q3 2023 vs $21.9M loss in Q3 2022; cash $252.2M as of Sep 30, 2023.
- Entered agreement with BMS for mavacamten rights in China and other Asian markets for $350M total consideration.
- Phase 3 TP-03 for Demodex blepharitis: mite eradication significant (p<0.001), collarette cure not significant (p=0.15); plans NDA filing.
- Board initiated comprehensive strategic review in October 2023; update expected first half 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1831283/000183128323000124/0001831283-23-000124-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1831283/000183128323000124/lian-20231113.htm
  HTML page:      https://secwatch.observer/filing/0001831283-23-000124

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer